Background Metabolic syndrome (MetS) is an important etiologic and prognostic factor for cancer, but few studies have assessed hospitalization outcomes among patients with both conditions. Methods Data was obtained from the Healthcare Cost and Utilization project Nationwide Inpatient Sample (HCUP-NIS). Study variables were assessed using ICD-9 codes on adults aged 40 years and over admitted to a US hospital between 2007 and 2011 with primary diagnosis of either breast, colorectal, or prostate cancer. We examined in-hospital mortality, post-surgical complications, and discharge disposition among cancer patients with MetS and compared with nonMetS patients. 1.03-1.39) and prostate (OR: 1.22, 95% CI: 1.09-1.37) cancer patients with MetS were higher, but lower by 7% among colorectal cancer patients with MetS. Additionally, breast (OR: 1.21, 95% CI: 1.11-1.32) and colorectal (OR: 1.06, 95% CI: 1.01-1.11) cancer patients with MetS had significantly higher odds for discharge to a skilled nursing facility compared with those without MetS, but this was not statistically significant among prostate cancer patients. Conclusions Adverse health outcomes were significantly higher among hospitalized patients with a primary diagnosis of cancer and MetS. Future studies are needed to identify clinical strategies for detecting and managing patients with MetS to reduce the likelihood of poor inpatient outcomes.
Introduction
Incidence rates for cancer and metabolic syndrome (MetS) have continued to increase dramatically in the USA and globally [34] . MetS is defined clinically as a cluster of interrelated biochemical conditions that include abdominal obesity, insulin resistance, dyslipidemia, and hypertension, and this condition has been associated with significantly increased risk for coronary heart disease, stroke, and type 2 diabetes [8, 24, 27, 33] . Recent epidemiologic evidence also suggests that MetS is an important etiologic factor for the development of cancer [47] , as well as poor prognosis for common cancer types including breast and colorectal cancer [20] . The prevalence of both MetS and cancer increases dramatically with age [46] , and with the rapid aging of the US population, adverse health outcomes for millions of adults, as well as healthcare costs, are likely to be significant [11] .
Currently, at least a third of the general US adult population meet the current clinical criteria for MetS based on analysis of the National Health and Nutritional Survey (NHANES 2003 (NHANES -2012 , with prevalence increasing to about 50% among those ages 60 years and older [1] . Individual components such as obesity [15] , diabetes [6, 37] , and hypertension [19, 23] have long been shown to increase the risk of medical complications, overall and cancer-specific mortality. However, health outcomes among hospitalized patients, who are likely older, more vulnerable, and with more severe health-related conditions, have not been well evaluated. Prior studies have reported strong positive associations between MetS and incidence and mortality due to breast [12, 20] , colorectal [5, 20] , liver [20] , and bladder cancers [20] , but hospitalized patients, particularly those with the most common cancer types in US adults (breast, prostate, and colorectal cancer), need further study. Hence, the purpose of this study is to examine health outcomes, specifically in-hospital mortality, post-surgical complications, and discharge disposition, among hospitalized cancer patients with a clinical diagnosis of MetS.
Methods
Study Population This cross-sectional study was conducted among breast, colorectal, and prostate cancer patients ages 40 years and older admitted to a US hospital between 2007 and 2011. Clinical data were obtained from the Healthcare Cost and Utilization Project (HCUP) Nationwide Inpatient Sample (NIS), which covers over 1000 hospitals in the USA and includes data on over seven million hospital stays. Further details about NIS can be obtained from http://www.hcupus. ahrq.gov/nisoverview.jsp.
Clinical and Individual Variables
International Classification of Disease, ninth edition ICD-9 codes for breast (ICD-9 codes: 174.x), colorectal (ICD-9 codes: 153.x, 154.0-154.3, 154.8), and prostate cancer (ICD-9 code: 185) recorded during admissions were assessed. Patients in whom the diagnosis of interest was not coded in first two diagnostic fields were excluded in order to exclude patients with underlying conditions. In addition, data on race, age, gender, area-level income, residential region, and insurance status were obtained from the NIS dataset. As cancer stage data is not captured in the dataset, a proxy cancer stage variable was created using the clinical criteria of disease staging, with patients categorized as metastatic when ICD-9 code indicated metastatic disease to other organs (196.x, 197.x, 198.x, 199 .0-199.1) and non-metastatic when those codes were absent. Several studies have used similar staging criteria using the HCUP-NIS database [4] . Hospital length of stay was calculated by subtracting the number of days between admission and discharge, with same-day stays coded as 0. Surgical treatment for breast, colorectal, and prostate cancer was classified using diagnostic and procedure codes similar to those used in prior studies with HCUP NIS data (ICD-9 codes: breast: 85. 41 [7] previously examined in the NIS database [31] and Surveillance, Epidemiology, and End Results-Medicare database [42] . A modified Deyo comorbidity index [4] was created to account for the number of comorbid conditions present upon admission among patients, and those included myocardial infarction, chronic heart failure, peripheral vascular disease, cerebrovascular disease, dementia, cardio-pulmonary disease, rheumatic disease, peptic ulcer disease, mild liver disease, hemiplegia, paraplegia, renal disease, liver disease, and HIV/AIDS.
Outcome Measures
The main study outcomes assessed for cancer patients were in-hospital mortality, post-surgical complications, and discharge disposition. In-hospital mortality was defined as deaths occurring during hospitalization; postsurgical complication was defined using ICD-9 codes associated with mechanical wounds, infection, renal, gastrointestinal, cardiovascular or pulmonary complications, as well as intra-operative complications. Discharge disposition is based on whether patients are discharged to recover at home or in other facilities such as nursing homes, and was classified into the following: (1) routine discharge: discharged to home or self-care; (2) discharge to a skilled nursing facility; (3) expired/died; and (4) other-classified as discharged due to any other reasons not stated above [10, 16] .
Statistical Analysis Descriptive statistics was conducted using Chi-square tests for categorical variables and t test for continuous variables, and the proportion of cancer in patients with MetS was assessed. Multivariable logistic regression analysis was used to determine the association between MetS and in-hospital mortality, complications, and discharge disposition separately for breast cancer in women only, prostate cancer in men only, and colorectal cancer in both men and women. All models were adjusted for age, race, stage, income, insurance and residential region, number of comorbidities, treatment, stage, and length of stay. Additionally, models for discharge disposition and in-hospital mortality were also adjusted for complications, and models for colorectal cancer were also adjusted for gender. All statistical analyses were performed with SAS 9.4 (Cary, NC).
Results
MetS was present in 5.2, 6.9, and 5.5% of hospitalized breast (70,916), colorectal (152,952), and prostate (87,623) cancer patients, respectively (Table 1) . MetS was more prevalent in the older age groups of 60-69 years (7.3% in breast, 8.6% in colorectal, and 6.2% in prostate patients) compared with younger age groups (1.4% in breast, 2.6% in colorectal, and 2.9% in prostate cancer). For breast (8.% vs. 4.5%), colorectal (7.4% vs. 6.7%), and prostate (7.6% vs. 4.9%) cancer patients, MetS prevalence was higher among Blacks compared to Whites. In addition, patients residing in the lowest socioeconomic status (SES) regions had higher prevalence of MetS compared with those in the highest SES regions across all three cancer types. Regardless of cancer type, patients on Medicare had much higher MetS prevalence compared with those with private or other insurance types.
After adjusting for demographics, SES, insurance, and stage (Table 2) (Table 3 ). Increasing number of comorbid conditions also increased the odds of post-surgical complications among breast cancer patients (OR: 1.10, 95% CI: 1.03-1.17), but reduced the odds among colorectal cancer patients (OR: 0.90, 95% CI: 0.88-0.92). Breast (OR: 1.21, 95% CI: 1.11-1.32) and colorectal (OR: 1.06, 95% CI: 1.01-1.11) cancer patients with MetS were significantly more likely to be discharged to a skilled nursing facility compared with those without MetS (Table 4) . Prostate cancer patients with MeS were also 10% more likely to be discharged to skilled nursing facilities; however, this was not statistically significant.
Discussion
In a large dataset of hospitalized cancer patients, we observed that 5 to 7% of breast, colorectal, and prostate cancer patients met the criteria for MetS using the NCEP ATP III definition [7] . The observed prevalence of MetS among hospitalized cancer patients increased with age and was much higher among Blacks and Hispanics compared with Whites, and higher among residents of lower SES regions compared with higher SES regions. These demographic patterns are similar to those observed in the general US population [1] , and other studies have reported a prevalence of about 9% among patient populations in the HCUP NIS [31] . About a third of the general US adult population currently meets the criteria for MetS, with significantly increasing trends observed in the past few decades [41] . Differences in the availability of relevant data items in routine healthcare claim databases such as the HCUP likely contributed to our observed lower estimate. Nevertheless, significant increases in the prevalence of MetS are expected to continue due to demographic changes (due to the aging of the US population) and trends in lifestyle risk factors (such as obesity, physical activity, and diet). These risk factors also independently contribute to cancer risk and prognosis, making the assessment of the impact of metabolic syndrome on cancer outcomes highly relevant.
We observed that breast, colorectal, and prostate cancer patients with MetS had lower odds of in-hospital mortality, but higher odds of post-surgical complications and discharge to skilled nursing facilities. Other studies have reported a positive association between MetS and cancer mortality [17, 25, 43] with result showing increased risk of cancer-related mortality among individuals with MetS, and other studies have reported increased risk of post-surgical complications among patients with MetS [30] . Our finding of an inverse association between MetS and in-hospital mortality may be due to several factors: (1) differences in the specific MetS criteria used, (2) tumorspecific differences in the association between MetS and cancer mortality that may be masked by examining overall cancer mortality, and/or (3) differences in study population examined. In this study, we focused on hospitalized cancer patients, who are likely to be at more advanced stages of disease and hospitalized for surgery or treatment of other cancer-related complications. This study population is also unique in several ways. For instance, the severity of the cancer diagnosis and complicated treatment process may have led to mis-classification of MetS status if relevant data on diabetes, cholesterol, or BMI are not routinely captured/ recorded in the medical records. In addition, an underlying MetS condition may be considered secondary to the primary cancer diagnosis during admission, and thus not addressed or evaluated during hospitalization. In addition, since MetS is associated with poorer hospitalization outcomes [9, 36, 38] , this may have resulted in our observed higher odds of post-surgical complications and non-routine discharge, in which case mortality outcomes will occur outside of the hospital setting and thus will not be captured in the dataset.
There were increased odds of post-operative complications among breast and prostate cancer patients with MetS, but decreased odds for patients with colorectal cancer. This may be due to differences in the types of surgical procedures. A major innovation in recent surgical techniques was the development of laparoscopic surgery for [21, 29, 45] . This less-invasive surgery type has been associated with significantly reduced rates of post-surgical complications, and a recent study observed that MetS was associated with poorer postsurgical outcomes following radical prostatectomy compared with those who received laparoscopic surgery [39] . We also observed significantly higher odds of breast and colorectal cancer patients with MetS to be discharged to skilled facilities. Our findings corroborate the existing literature showing that cancer patients with perioperative events, comorbidities, and surgical complications were at higher risk for rapid postoperative functional decline, leading to discharge to skilled facilities [16, 18, 44] . Taken together, these results suggest that the inverse association observed between MetS and in-hospital mortality is likely an artifact of the greater likelihood for these patients to experience post-surgical complications and to be discharged to nursing facilities. Given that millions of US adults currently meet the criteria for MetS, especially at older ages when the risk of chronic diseases like cancer is also highest, it is inevitable that a significant proportion of hospitalized patients will experience complications or adverse health outcomes more severe than indicated due to their current health condition. The question of a Comorbidities assessed based on ICD9 codes for the following: myocardial infarction, chronic heart failure, peripheral vascular disease, cerebrovascular disease, dementia, cardio-pulmonary disease, rheumatic disease, peptic ulcer disease, mild liver disease, hemiplegia, paraplegia, renal disease, liver disease, and HIV/AIDS *Cancer-specific surgeries whether health outcomes among cancer patients can be improved by controlling or eliminating MetS awaits large prospective studies. However, there is growing recognition of the importance of MetS as a significant public health issue, due to its independent association with worse health outcomes, as well as its role as an etiologic and/or prognostic risk factor for many other chronic diseases including cardiovascular diseases, stroke, chronic kidney diseases, and Alzheimer's disease. MetS is also associated with increased healthcare utilization, longer hospital stay, increased healthcare costs, and need for post-hospitalization care. A critical need will be to identify which approaches should be taken to address or resolve components of MetS among pre-, peri-, or postoperative patients, who are at increased risk of complications.
Hospitalized cancer patients with MetS may benefit from holistic clinical approaches to recognize components of MetS and its potential impact on health outcomes, and management strategies combining nutritional changes (e.g., lowcarbohydrate dietary patterns shown to improve HDL, glucose, and HbA1C levels [13, 14, 22] , prescribed physical a Comorbidities assessed based on ICD9 codes for the following: myocardial infarction, chronic heart failure, peripheral vascular disease, cerebrovascular disease, dementia, cardio-pulmonary disease, rheumatic disease, peptic ulcer disease, mild liver disease, hemiplegia, paraplegia, renal disease, liver disease, and HIV/AIDS *Cancer-specific surgeries activity (e.g., 30-min moderate physical activity 3-4 days/ week to improve blood pressure and glycemic control [28, 40] ), and/or the use of statins as lipid-lowering agents [35] . Future studies will be required to formally evaluate whether these combined behavioral/lifestyle approaches among cancer patients may improve post-operative outcomes and improve survival. Several strengths and limitations are relevant to these study results. First, there is very little direct evidence regarding inpatient outcomes among adults with clinical diagnoses of MetS and cancer, despite the high prevalence of MetS in US adults, the common risk factors shared by both conditions, and the vulnerability of hospitalized patients. Second, use of the Nationwide Inpatient Survey provided objective clinical claims data on MetS and cancer diagnosis on a large sample of US adults, with baseline socio-demographic data that allowed us to adjust for potential confounders. As with most studies based on administrative claim database, the study was also subject to several limitations. First, our operational definition of MetS relied exclusively on ICD-9 codes documented in the NIS database and may be vulnerable to misclassification and under-classification especially for MetS. The definition of MetS is ever-evolving [26] and included measurements of cholesterolemia, triglyceridemia, fasting plasma glycemia, and waist circumference. These may not always be assessed during admission for a primary diagnosis of cancer or may not be consistently recorded as diagnosis codes, potentially explaining the lower prevalence of MetS in our study sample. MetS was defined here based on the presence of diagnosis codes for at least three out of five components, following the definition proposed by the US National Cholesterol Education Program Adult Treatment Panel III [7] and similar to the methodology reported by other investigators [1, 31, 42] . Second, due to the cross-sectional nature of the dataset, we are unable to directly assess causality or account for individuals who have MetS components that are well controlled with medication. Nevertheless, we observed significantly worse health outcomes among patients with clinical diagnoses of MetS and cancer that warrant the early identification of these patients and formulation of clinical strategies to manage or eliminate components of MetS prior to surgery. Future studies are also needed to provide critical information regarding prevention and treatment strategies most appropriate for cancer patients, especially those who are sicker and hospitalized.
In conclusion, hospitalized patients with MetS and clinical diagnosis of breast, colorectal, and prostate cancer were less likely to experience in-hospital mortality, but were more likely to experience post-surgical complications and non-routine discharge to skilled nursing facilities. Clinical strategies for timely identification and control of MetS components may go a long way in reducing these adverse health outcomes among hospitalized patients.
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